All In Biotech

Drug Trial Radar · NCT06444113

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

A Phase IV, Prospective, Multicenter, Open-label, Mother-milk Study to Evaluate Ofatumumab Concentration in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis Receiving Ofatumumab

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Nov 25, 2024

Primary completion

Feb 20, 2026

Study completion Oct 29, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum.

Conditions

  • Multiple Sclerosis

Interventions

  • OfatunumabDrug

    No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of ofatumumab in breast milk.Time frame: (pre-dose) on the day of second (or subsequent) maintenance dose, then 7, 14, 21, 28 days after the second (or subsequent) maintenance dose"

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • UCSF

    San Francisco, California

  • UC Health Neuroscience Ctr

    Aurora, Colorado

  • Northwestern Medicine Northwestern University

    Winfield, Illinois

  • Brigham and Womens Hospital

    Brookline, Massachusetts

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Tübingen, Germany

  • Novartis Investigative Site

    Munich, Bavaria, Germany

  • Novartis Investigative Site

    Foggia, FG, Italy

  • Novartis Investigative Site

    Bialystok, Poland

  • Novartis Investigative Site

    Kielce, Poland

  • Novartis Investigative Site

    Cambridge, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Oxford, United Kingdom

  • Novartis Investigative Site

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.